HEMOBLAST Pivotal Clinical Investigation

Not Applicable

Completed

Conditions: Hemostasis

Interventions: Device: Absorbable gelatin sponge, USP with thrombin
Device: HEMOBLAST Bellows

Registration Number: NCT02780869

Lead Sponsor: Biom'Up France SAS

Brief Summary: The purpose of this prospective, randomized, controlled study is to evaluate the safety and efficacy of a new hemostatic device (HEMOBLAST™ Bellows) compared to a control device, absorbable gelatin sponge USP with thrombin.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 258

Inclusion Criteria

• Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity surgery;
- Subject or an authorized legal representative is willing and able to give prior written informed consent for investigation participation;
- Subject undergoing cardiothoracic surgery is not allergic to protamine; and
- Subject is 21 years of age or older.

Exclusion Criteria

• Subject is undergoing a laparoscopic, thoracoscopic, or robotic surgical procedure;
- Subject is undergoing a neurologic surgical procedure;
- Subject is undergoing a spinal surgical procedure;
- Subject is undergoing an emergency surgical procedure;
- Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively breast-feeding;
- Subject has a clinically significant coagulation disorder or disease, defined as a platelet count < 100,000 per microliter or International Normalized Ratio > 1.5 within 4 weeks of surgery;
- Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 days before surgery;
- Subject receiving antiplatelet medications within 5 days prior to surgery;
- Subject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within 7 days prior to surgery;
- Subject has an active or suspected infection at the surgical site;
- Subject has had or has planned to receive any organ transplantation;
- Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
- Subject has ASA classification of 5;
- Subject has a life expectancy of less than 3 months;
- Subject has a known psychiatric disorder, which in the opinion of the Principal Investigator, would preclude the subject from completing this clinical study;
- Subject has a documented severe congenital or acquired immunodeficiency;
- Subject has religious or other objections to porcine, bovine, or human components;
- Subject in whom the investigational or control device will be used at the site of a valve replacement or repair;
- Subject in whom the investigational or control device will be used at the site of a synthetic graft or patch implant;
- Subject is currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent; and
- Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator.

Intraoperative Eligibility Criteria:

Subject does not have an active or suspected infection at the surgical site;
Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to target bleeding site (TBS) identification and treatment;
Subject in whom the Investigator is able to identify a TBS for which any applicable conventional means for hemostasis are ineffective or impractical; and
Subject has a TBS with an SBSS score of 1, 2, or 3.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Absorbable gelatin sponge, USP with thrombin	Absorbable gelatin sponge, USP with thrombin
Investigational	HEMOBLAST Bellows	HEMOBLAST Bellows

Primary Outcome Measures

Name	Time	Method
Proportion of Subjects Achieving Hemostasis	Intraoperative, 6 Minutes Post-Application	The proportion of subjects achieving hemostasis at 6 minutes post-hemostat application was calculated. Hemostasis was defined as a grade of 0 (None/Dry) on the Surface Bleeding Severity Scale, with additional grades, ranging from 1 (Minimal/Oozing) to 5 (Extreme/Gushing), considered a failure of hemostasis.

Secondary Outcome Measures

Name	Time	Method
Product Preparation Time	Intraoperative	The average time from the opening of the package to the product being ready to use, measured in minutes and seconds.
Proportion of Subjects Achieving Hemostasis	Intraoperative, 3 Minutes Post-Application	The proportion of subjects achieving hemostasis at 3 minutes post-hemostat application was calculated

Trial Locations

Locations (17): Washington University in St. Louis
🇺🇸
Saint Louis, Missouri, United States
Queens Medical Center
🇺🇸
Honolulu, Hawaii, United States
Icahn School of Medicine at Mount Sinai
🇺🇸
New York, New York, United States
Columbia University Medical Center / New York Presbyterian Hospital
🇺🇸
New York, New York, United States
Hunstad Kortesis Center
🇺🇸
Huntsville, North Carolina, United States
Lotus Clinical Research
🇺🇸
Pasadena, California, United States
Intermountain Liver Disease and Transplant Center
🇺🇸
Murray, Utah, United States
Spectrum Medical
🇺🇸
Danville, Virginia, United States
Dartmouth Hitchcock Medical Center
🇺🇸
Hanover, New Hampshire, United States
University of Virginia
🇺🇸
Charlottesville, Virginia, United States
CORE Institute
🇺🇸
Phoenix, Arizona, United States
University of California Los Angeles
🇺🇸
Los Angeles, California, United States
University of Southern California
🇺🇸
Los Angeles, California, United States
Miami Plastic Surgery
🇺🇸
Miami, Florida, United States
Suburban Hospital - Johns Hopkins Medicine
🇺🇸
Bethesda, Maryland, United States
University of North Carolina at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
Duke University
🇺🇸
Durham, North Carolina, United States